For a female patient taking phenytoin 100 mg three times daily, what levetiracetam dose should be initiated?

Levetiracetam Dosing in Patients on Phenytoin

For a patient taking phenytoin 100 mg three times daily, initiate levetiracetam at the standard dose of 500 mg twice daily (1000 mg/day), with consideration for dose escalation to 1000 mg twice daily (2000 mg/day) or higher based on clinical response, as phenytoin co-administration increases levetiracetam clearance by approximately 43%.

Rationale for Standard Initial Dosing

The FDA-approved dosing for levetiracetam as adjunctive therapy for partial onset seizures in adults begins at 1000 mg/day given as 500 mg twice daily 1. This starting dose applies regardless of concomitant antiepileptic medications. Treatment can be escalated by 1000 mg/day increments every 2 weeks up to a maximum of 3000 mg/day 1.

Impact of Phenytoin Co-Administration

Phenytoin significantly affects levetiracetam pharmacokinetics. Recent population pharmacokinetic modeling demonstrates that phenytoin co-administration increases levetiracetam clearance by 43.1% 2. This means patients on phenytoin will achieve lower levetiracetam concentrations at any given dose compared to those not receiving enzyme-inducing antiepileptics.

However, earlier pooled analyses from phase III trials showed more modest effects, with enzyme-inducing AEDs (including phenytoin) causing only slight reductions in levetiracetam concentrations and half-life 3. A dedicated interaction study using stable isotope techniques confirmed that levetiracetam does not alter phenytoin pharmacokinetics 4.

Practical Dosing Algorithm

Initial dosing:

• Start with 500 mg twice daily (standard FDA-approved starting dose)
• Monitor clinical response over 2 weeks

Dose escalation strategy:

• If seizure control is inadequate after 2 weeks, increase to 1000 mg twice daily (2000 mg/day)
• Further escalation to 1500 mg twice daily (3000 mg/day) may be necessary given the enhanced clearance from phenytoin
• Patients on phenytoin are more likely to require doses at the higher end of the therapeutic range

Key considerations:

• The therapeutic serum concentration range for levetiracetam is 12-46 mg/L 2
• Monte Carlo simulations show that patients receiving phenytoin have reduced probability of achieving therapeutic targets, particularly those with normal or augmented renal function 2
• More frequent or higher dosing is often needed in phenytoin-treated patients compared to those on non-enzyme-inducing regimens

Monitoring Parameters

• Clinical seizure control is the primary endpoint
• Therapeutic drug monitoring may be helpful if seizures persist despite dose escalation, particularly to confirm whether subtherapeutic levels are due to phenytoin interaction
• Assess for adverse effects (somnolence, dizziness, asthenia) which are dose-dependent 1
• No routine laboratory monitoring is required beyond complete blood count 5

Common Pitfalls to Avoid

Do not assume standard doses will be adequate. The 43% increase in clearance means many patients on phenytoin will need higher maintenance doses than those on non-enzyme-inducing regimens. Be prepared to escalate to 2000-3000 mg/day.

Do not adjust phenytoin dosing. Levetiracetam does not affect phenytoin levels 4, so the patient's current phenytoin 100 mg three times daily can remain unchanged.

Do not use once-daily dosing. Twice-daily administration is required for levetiracetam; once-daily dosing is only appropriate for extended-release phenytoin formulations, not levetiracetam 1, 6.